avadel
pharmaceuticals
announces
leadership
transition
jordan
dubow
stepping
cmo
continue
consultant
company
nda
submission
review
seasoned
industry
veteran
avadel
board
member
mark
mccamish
work
management
provide
direct
leadership
program
dublin
ireland
globe
newswire
avadel
pharmaceuticals
plc
nasdaq
avdl
company
focused
developing
investigational
formulation
sodium
oxybate
designed
treat
excessive
daytime
sleepiness
cataplexy
patients
narcolepsy
announced
today
jordan
dubow
stepping
chief
medical
officer
pursue
another
opportunity
continue
consultancy
role
order
support
company
filing
review
anticipated
approval
new
drug
application
nda
fda
mark
mccamish
independent
director
avadel
board
directors
accomplished
industry
executive
years
drug
development
experience
assume
direct
leadership
role
filing
working
avadel
ceo
greg
divis
dubow
rest
team
ensure
continuity
program
including
completeness
timeliness
nda
submission
thank
jordan
hard
work
dedication
chief
medical
officer
including
important
role
played
acceleration
reporting
data
pivotal
phase
study
produced
robust
statistically
significant
results
across
primary
endpoints
phase
complete
believe
addition
mark
extensive
experience
direct
leadership
filing
serves
strengthen
internal
external
teams
include
world
class
capabilities
fields
clinical
development
regulatory
affairs
cmc
result
utmost
confidence
team
confident
change
impact
timing
planned
nda
filing
said
divis
continue
excited
market
potential
approved
execute
market
preparation
activities
continue
evaluate
strategic
options
including
sale
merger
commercialization
maximize
shareholder
want
thank
greg
avadel
team
board
support
personal
decision
take
new
role
outside
avadel
focused
developing
gene
therapies
stated
dubow
excited
proud
progress
made
advancing
development
program
potential
formulation
sodium
oxybate
positive
impact
lives
narcolepsy
patients
suffering
excessive
daytime
sleepiness
cataplexy
look
forward
continuing
support
program
avadel
team
new
capacity
remain
highly
confident
clinical
data
timing
nda
filing
commercial
board
committed
supporting
avadel
team
nda
preparation
review
process
since
joining
board
actively
overseeing
development
regulatory
plan
remain
confident
team
well
positioned
finish
filing
without
delay
stated
mccamish
approved
would
first
therapy
address
excessive
daytime
sleepiness
cataplexy
patients
narcolepsy
result
avadel
board
remains
confident
potential
important
treatment
option
narcolepsy
patients
disrupt
estimated
sodium
oxybate
mccamish
joined
avadel
board
directors
december
internationally
recognized
expert
drug
development
regulatory
affairs
manufacturing
recently
president
chief
executive
officer
forty
seven
moving
magrolimab
early
development
registration
trials
led
gilead
acquisition
company
billion
april
prior
forty
seven
mccamish
global
head
biopharmaceutical
development
sandoz
international
novartis
company
led
filing
ten
blas
last
three
years
tenure
investigational
formulation
cr
sodium
oxybate
march
company
completed
study
pivotal
randomized
phase
trial
assess
efficacy
safety
treatment
excessive
daytime
sleepiness
cataplexy
patients
suffering
narcolepsy
granted
orphan
drug
designation
food
drug
administration
fda
treatment
narcolepsy
designation
granted
plausible
hypothesis
may
clinically
superior
formulation
sodium
oxybate
already
approved
fda
indication
particular
may
safer
due
ramifications
associated
dosing
regimen
previously
approved
product
avadel
pharmaceuticals
plc
avadel
pharmaceuticals
plc
nasdaq
avdl
emerging
biopharmaceutical
company
company
primary
focus
development
fda
approval
investigational
formulation
sodium
oxybate
designed
treat
excessive
daytime
sleepiness
cataplexy
patients
narcolepsy
information
please
visit
footnote
annualized
xyrem
revenues
jazz
pharmaceuticals
full
year
fourth
quarter
financial
results
press
release
february
cautionary
disclosure
regarding
statements
press
release
includes
statements
within
meaning
section
securities
act
section
securities
exchange
act
statements
relate
future
expectations
beliefs
plans
strategies
objectives
results
conditions
financial
performance
prospects
events
statements
include
limited
planned
submission
nda
fda
commercial
launch
approved
cases
statements
identified
use
words
may
could
believe
expect
look
forward
track
guidance
anticipate
estimate
project
next
steps
similar
expressions
negatives
thereof
applicable
statements
based
estimates
assumptions
made
within
bounds
knowledge
business
operations
consider
reasonable
however
business
operations
subject
significant
risks
result
assurance
actual
results
including
without
limitation
continued
advancement
development
benefits
cost
savings
sale
hospital
products
results
business
operations
differ
materially
results
contemplated
statements
factors
could
cause
actual
results
differ
expectations
statements
include
risk
file
nda
timely
basis
risk
fda
accept
nda
approve
risk
impact
current
pandemic
financial
results
results
operations
could
greater
anticipate
risks
uncertainties
described
risk
factors
section
part
item
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
subsequent
sec
filings
statements
speak
date
made
guarantees
future
performance
accordingly
place
undue
reliance
statements
undertake
obligation
publicly
update
revise
statements
except
required
law
contacts
investor
contacts
tom
mchugh
chief
financial
officer
phone
email
tmchugh
tim
mccarthy
lifesci
advisors
llc
phone
email
tim
